Tag: GlobeNewswire

Major Institutional Formulary Win Expands Arbli^™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially

Arbli^™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually

COMMACK, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli^™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formulary of three (3) leading U.S. pediatric academic medical centers and hospitals specializing in the treatment of children with complex and chronic medical conditions.

The formulary additions represent an important commercial milestone for Arbli^™ and expands the product’s presence within the institutional and pediatric healthcare market. Arbli^™ is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric and other patient populations with difficulty swallowing tablets.

Arbli^™ addresses a large and established U.S. losartan market representing approximately $219 million in sales and approximately 72 million prescriptions annually (IQVIA MAT Apr 2026). By eliminating the variability and inconvenience associated with pharmacy compounding, Scienture believes that Arbli^™ provides healthcare professionals with a consistent, convenient and scalable ready-to-use treatment option.

Arbli^™ is indicated for the treatment of hypertension in adults and pediatric patients six years of age and older. Its ready-to-use 10 mg/mL oral suspension provides flexible dosing without the need for extemporaneous pharmacy compounding, attributes that are particularly relevant in pediatric care, where patients may require individualized dosing or have difficulty swallowing conventional tablets.

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture, commented, “The commercial rollout of Arbli^™ has continued to gain momentum, with wholesale orders increasing sequentially and adoption expanding across key healthcare channels. These formulary additions represent an important growth milestone in the commercialization of Arbli^™ and, importantly, its adoption within the pediatric healthcare setting, where the product provides much needed patient benefits. With the U.S. losartan market representing approximately $219 million in sales annually, even modest market penetration could represent a meaningful commercial opportunity for Arbli^™. The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as we continue to expand Arbli^™’s market penetration. We believe the combination of expanding institutional adoption, increasing wholesale orders and a highly attractive market opportunity provides a strong foundation for continued growth.”

“We believe this is just the beginning of the opportunity for Arbli^™ within the pediatric hospital market,” added Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture. “We believe the addition of Arbli^™ by leading pediatric academic medical centers can help support our efforts to expand adoption across other institutions. We remain focused on building broader hospital and institutional access while continuing to expand payer coverage, pharmacy availability and distribution nationwide.”

The new formulary placements build upon Scienture’s broader commercialization strategy for Arbli^™, which is focused on expanding commercial and government payer coverage, pharmacy availability, institutional adoption and distribution access. The Company intends to continue pursuing hospital and institutional formulary opportunities, including within pediatric healthcare settings, as it works to broaden Arbli^™ adoption and increase patient access nationwide.

About Arbli^™

Arbli^™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli^™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli^™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli^™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli^™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli^™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli^™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli^™ is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

• Do not take Arbli^™ when pregnant. When pregnancy is detected, discontinue Arbli^™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli^™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Do not co-administer Arbli^™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli^™ in patients with renal impairment (GFR <60 mL/min).
• Do not administer Arbli^™ in patients with severe hepatic impairment. Arbli^™ has not been studied in patients with severe hepatic impairment.
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli^™, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com

Major Institutional Formulary Win Expands Arbli^™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially

Arbli^™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually

COMMACK, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli^™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formulary of three (3) leading U.S. pediatric academic medical centers and hospitals specializing in the treatment of children with complex and chronic medical conditions.

The formulary additions represent an important commercial milestone for Arbli^™ and expands the product’s presence within the institutional and pediatric healthcare market. Arbli^™ is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric and other patient populations with difficulty swallowing tablets.

Arbli^™ addresses a large and established U.S. losartan market representing approximately $219 million in sales and approximately 72 million prescriptions annually (IQVIA MAT Apr 2026). By eliminating the variability and inconvenience associated with pharmacy compounding, Scienture believes that Arbli^™ provides healthcare professionals with a consistent, convenient and scalable ready-to-use treatment option.

Arbli^™ is indicated for the treatment of hypertension in adults and pediatric patients six years of age and older. Its ready-to-use 10 mg/mL oral suspension provides flexible dosing without the need for extemporaneous pharmacy compounding, attributes that are particularly relevant in pediatric care, where patients may require individualized dosing or have difficulty swallowing conventional tablets.

Narasimhan Mani, President and Co-Chief Executive Officer of Scienture, commented, “The commercial rollout of Arbli^™ has continued to gain momentum, with wholesale orders increasing sequentially and adoption expanding across key healthcare channels. These formulary additions represent an important growth milestone in the commercialization of Arbli^™ and, importantly, its adoption within the pediatric healthcare setting, where the product provides much needed patient benefits. With the U.S. losartan market representing approximately $219 million in sales annually, even modest market penetration could represent a meaningful commercial opportunity for Arbli^™. The opportunity is particularly compelling given Scienture’s high gross margins, providing significant operating leverage as we continue to expand Arbli^™’s market penetration. We believe the combination of expanding institutional adoption, increasing wholesale orders and a highly attractive market opportunity provides a strong foundation for continued growth.”

“We believe this is just the beginning of the opportunity for Arbli^™ within the pediatric hospital market,” added Shankar Hariharan, Executive Chairman and Co-Chief Executive Officer of Scienture. “We believe the addition of Arbli^™ by leading pediatric academic medical centers can help support our efforts to expand adoption across other institutions. We remain focused on building broader hospital and institutional access while continuing to expand payer coverage, pharmacy availability and distribution nationwide.”

The new formulary placements build upon Scienture’s broader commercialization strategy for Arbli^™, which is focused on expanding commercial and government payer coverage, pharmacy availability, institutional adoption and distribution access. The Company intends to continue pursuing hospital and institutional formulary opportunities, including within pediatric healthcare settings, as it works to broaden Arbli^™ adoption and increase patient access nationwide.

About Arbli^™

Arbli^™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli^™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli^™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli^™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli^™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

Arbli^™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli^™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

INDICATION

Arbli^™ is an angiotensin II receptor blocker (ARB) indicated for:

• Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
• Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
• Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

IMPORTANT SAFETY INFORMATION

• Do not take Arbli^™ when pregnant. When pregnancy is detected, discontinue Arbli^™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli^™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
• Do not co-administer Arbli^™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli^™ in patients with renal impairment (GFR <60 mL/min).
• Do not administer Arbli^™ in patients with severe hepatic impairment. Arbli^™ has not been studied in patients with severe hepatic impairment.
• The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

About Hypertension

Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, such as Arbli^™, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com

Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall

Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies

THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, titled, “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall.” The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide, with the newly issued patent further strengthening its intellectual property position across multiple nerve-targeted therapies and denervation applications.

The newly issued patent protects the Company’s catheter-based transvascular intervention technologies designed to access tissue beyond the vessel wall and guide, optimize and validate therapy delivery using real-time physiological feedback.

Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix’s intellectual property position across major commercial markets.

“We believe the future of nerve-targeted therapy lies not only in identifying the appropriate neural target, but in enabling physicians to precisely access that target, deliver therapy with objective physiological feedback, and determine whether the intended therapeutic effect has been achieved,” commented Brad Hauser, Chief Executive Officer of Autonomix Medical. “This patent strengthens protection around the core technologies that enable catheter-based transvascular intervention, reinforcing the differentiated capabilities of our platform and supporting our long-term strategy to advance next-generation neuromodulation technologies across multiple clinical applications.”

The newly granted Canadian patent covers catheter-based transvascular (intraluminal) tools and systems designed to operate from within a bodily lumen, where deployable probes penetrate into and/or through a lumen wall to access tissue and nerves located outside the vessel. The patent covers multi-site electrophysiological sensing, incorporating sensing at a target site, secondary site, and reference site to improve, for example, signal quality and procedural confidence. The patent also encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to assess treatment effect and procedural outcomes.

In addition, the patent includes closed-loop control capabilities that enable systems to adjust stimulation or therapeutic energy delivery in real time based on live electrophysiological feedback. This supports adaptive neuromodulation and more data-driven procedural workflows. The patent further covers a broad range of electrophysiological signal types and therapeutic modalities, with potential applicability across multiple nerve-targeted indications. It also includes system-level claims covering control units configured to evaluate, guide, and optimize procedures using real-time electrophysiological data.

Autonomix has built a comprehensive intellectual property portfolio designed to provide broad, area-by-area protection across the body, encompassing core platforms for nerve mapping, signal processing, and controlled micro-ablation, along with application-specific innovations across multiple organ systems. With issued patents in the United States, Canada, Europe, and other key international jurisdictions, and expirations extending into the late 2030s, the portfolio is structured to support multi-organ platform scalability and expansion into diverse clinical indications.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the Company’s planned U.S. clinical study, anticipated physician adoption, potential strategic partnerships, reimbursement discussions, the scope and commercial value of the Company’s intellectual property portfolio, and the potential applicability of the Company’s platform technology across multiple clinical indications and organ systems.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall

Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies

THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, titled, “Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within and/or Through a Lumen Wall.” The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide, with the newly issued patent further strengthening its intellectual property position across multiple nerve-targeted therapies and denervation applications.

The newly issued patent protects the Company’s catheter-based transvascular intervention technologies designed to access tissue beyond the vessel wall and guide, optimize and validate therapy delivery using real-time physiological feedback.

Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix’s intellectual property position across major commercial markets.

“We believe the future of nerve-targeted therapy lies not only in identifying the appropriate neural target, but in enabling physicians to precisely access that target, deliver therapy with objective physiological feedback, and determine whether the intended therapeutic effect has been achieved,” commented Brad Hauser, Chief Executive Officer of Autonomix Medical. “This patent strengthens protection around the core technologies that enable catheter-based transvascular intervention, reinforcing the differentiated capabilities of our platform and supporting our long-term strategy to advance next-generation neuromodulation technologies across multiple clinical applications.”

The newly granted Canadian patent covers catheter-based transvascular (intraluminal) tools and systems designed to operate from within a bodily lumen, where deployable probes penetrate into and/or through a lumen wall to access tissue and nerves located outside the vessel. The patent covers multi-site electrophysiological sensing, incorporating sensing at a target site, secondary site, and reference site to improve, for example, signal quality and procedural confidence. The patent also encompasses methods for assessing procedural completion based on electrophysiological signal processing, including detection of changes in neural activity patterns to assess treatment effect and procedural outcomes.

In addition, the patent includes closed-loop control capabilities that enable systems to adjust stimulation or therapeutic energy delivery in real time based on live electrophysiological feedback. This supports adaptive neuromodulation and more data-driven procedural workflows. The patent further covers a broad range of electrophysiological signal types and therapeutic modalities, with potential applicability across multiple nerve-targeted indications. It also includes system-level claims covering control units configured to evaluate, guide, and optimize procedures using real-time electrophysiological data.

Autonomix has built a comprehensive intellectual property portfolio designed to provide broad, area-by-area protection across the body, encompassing core platforms for nerve mapping, signal processing, and controlled micro-ablation, along with application-specific innovations across multiple organ systems. With issued patents in the United States, Canada, Europe, and other key international jurisdictions, and expirations extending into the late 2030s, the portfolio is structured to support multi-organ platform scalability and expansion into diverse clinical indications.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, expectations regarding the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions, the Company’s planned U.S. clinical study, anticipated physician adoption, potential strategic partnerships, reimbursement discussions, the scope and commercial value of the Company’s intellectual property portfolio, and the potential applicability of the Company’s platform technology across multiple clinical indications and organ systems.

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.

“Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full-year outlook.”

Mr. Essig continued, “While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Importantly, we remain encouraged by the progress we are making across the broader business, including improving product availability, the return of key products to market, and strengthening commercial execution.”

Update on Cincinnati Facility

As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed on the second quarter earnings call, flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruption to the site. The facility manufactures and supports several products within the Company’s Specialty Surgical Technologies portfolio.

Since the event, Integra has continued to execute its business continuity and recovery plans. The Company has utilized available inventory, activated established alternate sources of supply for certain products, and advanced restoration activities at the Cincinnati facility. These actions are intended to support customers and mitigate disruption while recovery efforts continue.

Based on its current assessment, Integra estimates that the flooding related supply disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million. The Company expects a return to full manufacturing operations at the site during the second quarter of 2027.

Integra maintains property and business interruption insurance covering the Cincinnati facility. Based on its current assessment, the Company expects insurance recoveries to mitigate a substantial portion of the earnings impact associated with the disruption throughout the recovery period and until the facility returns to full manufacturing capacity. The Company continues to work with its insurance carrier to assess and document recoverable losses associated with the event, including both property damage and business interruption claims.

Preliminary Third Quarter Results and Updated Full-Year Guidance

For the third quarter of 2026, the Company expects to report revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59. The preliminary results as set forth above are unaudited and remain subject to completion of the Company’s financial closing procedures.

For the full year 2026, the Company is updating its reported revenue outlook from a range of $1.654 billion to $1.695 billion to a range of $1.634 billion to $1.654 billion. The Company is updating its adjusted earnings per diluted share guidance from a range of $2.40 to $2.50 to a range of $2.30 to $2.40 and expects operating cash flow for the year to be approximately $190 million to $200 million.

The third quarter preliminary results and updated full-year guidance reflect revised assumptions regarding the expected impact of the July flooding event at the Cincinnati facility, as well as updated assumptions for the broader business for the remainder of the year.

The Company will report its third quarter 2026 financial results during a conference call in October 2026. A press release with the date, time and webcast information will be provided closer to the reporting date. The Company will provide additional information regarding its third quarter financial results and outlook for full-year 2026 at that time.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to: our preliminary unaudited results for the third quarter ended September 30, 2026; the preliminary estimated impact of the flooding event at our Cincinnati, Ohio manufacturing facility (the “Cincinnati facility”), including on revenue, adjusted earnings per diluted share and our financial condition and results of operations more generally; our fiscal 2026 guidance and our ability to deliver on such financial guidance; our expectations and progress in our recovery efforts, including timing and costs; and expected insurance coverage and recoveries. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra’s business and market, including: our ongoing assessment of the flooding event at the Cincinnati facility, related financial impacts, recovery efforts, potential asset impairments, unforeseen costs and insurance recoveries; and other risks identified under the heading “Risk Factors” included in item 1A of Integra’s Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Actual results could differ materially from anticipated or preliminary results or estimates. These forward-looking statements are made only as the date thereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com   

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.

“Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer. “Our teams have made significant progress executing recovery plans and supporting customers. As we have gained additional visibility into the recovery timeline and production ramp, we now have a clearer understanding of the expected impact on our third quarter results and full-year outlook.”

Mr. Essig continued, “While we are lowering our full-year revenue and adjusted EPS outlook for 2026, we continue to expect strong cash generation, including greater than $85 million of operating cash flow in the third quarter and approximately $190 million to $200 million for the full year. Importantly, we remain encouraged by the progress we are making across the broader business, including improving product availability, the return of key products to market, and strengthening commercial execution.”

Update on Cincinnati Facility

As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed on the second quarter earnings call, flooding at the Cincinnati facility in July 2026 caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruption to the site. The facility manufactures and supports several products within the Company’s Specialty Surgical Technologies portfolio.

Since the event, Integra has continued to execute its business continuity and recovery plans. The Company has utilized available inventory, activated established alternate sources of supply for certain products, and advanced restoration activities at the Cincinnati facility. These actions are intended to support customers and mitigate disruption while recovery efforts continue.

Based on its current assessment, Integra estimates that the flooding related supply disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million. The Company expects a return to full manufacturing operations at the site during the second quarter of 2027.

Integra maintains property and business interruption insurance covering the Cincinnati facility. Based on its current assessment, the Company expects insurance recoveries to mitigate a substantial portion of the earnings impact associated with the disruption throughout the recovery period and until the facility returns to full manufacturing capacity. The Company continues to work with its insurance carrier to assess and document recoverable losses associated with the event, including both property damage and business interruption claims.

Preliminary Third Quarter Results and Updated Full-Year Guidance

For the third quarter of 2026, the Company expects to report revenue of approximately $410 million to $412 million and adjusted earnings per diluted share of $0.55 to $0.59. The preliminary results as set forth above are unaudited and remain subject to completion of the Company’s financial closing procedures.

For the full year 2026, the Company is updating its reported revenue outlook from a range of $1.654 billion to $1.695 billion to a range of $1.634 billion to $1.654 billion. The Company is updating its adjusted earnings per diluted share guidance from a range of $2.40 to $2.50 to a range of $2.30 to $2.40 and expects operating cash flow for the year to be approximately $190 million to $200 million.

The third quarter preliminary results and updated full-year guidance reflect revised assumptions regarding the expected impact of the July flooding event at the Cincinnati facility, as well as updated assumptions for the broader business for the remainder of the year.

The Company will report its third quarter 2026 financial results during a conference call in October 2026. A press release with the date, time and webcast information will be provided closer to the reporting date. The Company will provide additional information regarding its third quarter financial results and outlook for full-year 2026 at that time.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra LifeSciences and its products, please visit www.integralife.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to: our preliminary unaudited results for the third quarter ended September 30, 2026; the preliminary estimated impact of the flooding event at our Cincinnati, Ohio manufacturing facility (the “Cincinnati facility”), including on revenue, adjusted earnings per diluted share and our financial condition and results of operations more generally; our fiscal 2026 guidance and our ability to deliver on such financial guidance; our expectations and progress in our recovery efforts, including timing and costs; and expected insurance coverage and recoveries. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Integra’s business and market, including: our ongoing assessment of the flooding event at the Cincinnati facility, related financial impacts, recovery efforts, potential asset impairments, unforeseen costs and insurance recoveries; and other risks identified under the heading “Risk Factors” included in item 1A of Integra’s Annual Report on Form 10-K for the year ended December 31, 2025, and information contained in subsequent filings with the Securities and Exchange Commission. Actual results could differ materially from anticipated or preliminary results or estimates. These forward-looking statements are made only as the date thereof, and Integra undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com   

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

Vilnius, Lithuania, Oct. 02, 2026 (GLOBE NEWSWIRE) —

As at the end of September 2026, the net asset value (NAV) of SUTNTIB AB Tewox decreased to EUR 44,775,595, compared to the previously determined NAV of EUR 45,190,557 at the end of August 2026.

The share price decreased to EUR 1.0696, from EUR 1.0795 at the end of August 2026. The pro-forma internal rate of return (IRR) decreased to 3.24%, compared to previously announced IRR of 3.51% at the end of August 2026.

Contact person for further information:

Paulius Nevinskas
Manager of the Investment Company
paulius.nevinskas@lordslb.lt
https://lordslb.lt/tewox_bonds/

Vilnius, Lithuania, Oct. 02, 2026 (GLOBE NEWSWIRE) —

As at the end of September 2026, the net asset value (NAV) of SUTNTIB AB Tewox decreased to EUR 44,775,595, compared to the previously determined NAV of EUR 45,190,557 at the end of August 2026.

The share price decreased to EUR 1.0696, from EUR 1.0795 at the end of August 2026. The pro-forma internal rate of return (IRR) decreased to 3.24%, compared to previously announced IRR of 3.51% at the end of August 2026.

Contact person for further information:

Paulius Nevinskas
Manager of the Investment Company
paulius.nevinskas@lordslb.lt
https://lordslb.lt/tewox_bonds/

Strengthens Executive Leadership Team to Accelerate Growth Plans as Company Seeks to Scale Innovative Drone Platforms Across Defense and Civilian Markets

FT. LAUDERDALE, FL, Oct. 02, 2026 (GLOBE NEWSWIRE) — / CORRECTING / Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) (“Duke Robotics” or the “Company”), a leader in advanced robotics and drone-based solutions for civilian and defense markets, today announced the appointment of Avi Levin as Chief Financial Officer, effective October 1, 2026. Mr. Levin succeeds Shlomo Zakai, who is expected to continue providing financial and corporate consulting services to the Company to support a seamless transition of financial operations.

The appointment comes as Duke Robotics enters an accelerated growth phase following its recent Nasdaq uplisting and the arrival of Chief Executive Officer Yiftach Kleinman. As the Company looks to scale commercial adoption of its drone platforms across defense and civilian markets, and expand its offerings, the Company believes Mr. Levin will play a key role in developing Duke’s financial strategy, capital allocation, and corporate initiatives to support its growing operational footprint and strategic expansion plans.

“Since assuming the role of Chief Executive Officer, my focus has been to accelerate our operational tempo and assemble the executive leadership required to execute our growth strategy,” said Yiftach Kleinman, Chief Executive Officer of Duke Robotics. “Duke is at a pivotal inflection point. In the civilian sector, our utility grid solutions are commercially validated and addressing an urgent need for power infrastructure resilience amid rising geopolitical challenges and surging energy demand associated with, among other things, artificial intelligence. In defense, our battle-tested platforms are advancing toward broader commercialization. Bringing on an executive of Avi’s caliber is central to pursuing this market opportunity. He brings a rare combination of deep capital markets experience, proven public company CFO leadership, and strategic transaction expertise that we believe will be instrumental in scaling our business. On behalf of our Board of Directors and the entire Company, I also want to thank Shlomo Zakai for his dedicated financial stewardship through our Nasdaq uplisting, and we look forward to his continued support.”

Mr. Levin is an accomplished financial executive and certified public accountant with more than two decades of corporate finance, capital markets, and institutional leadership experience across the United States and Israel. Throughout his career, he has raised more than $130 million through private placements and public offerings with Nasdaq-listed issuers. He previously served as Chief Financial Officer of Ability Inc. (NASDAQ: ABIL), where he helped lead three Nasdaq offerings, raising an aggregate of $78 million. He also served as Chief Financial Officer of RAD Data Communications, a leading global telecommunications provider, where he managed a 49-person global finance and IT organization across 11 subsidiaries and led the company’s official Nasdaq IPO readiness initiative. Mr. Levin also served as Chief Financial Officer of enterprise AI software provider BlackSwan Technologies where he was part of their institutional financing round. Most recently, he served as a senior financial advisor and executive consultant, advising late-stage technology companies on U.S. capital raising, IPO readiness, and strategic transactions.

Earlier in his career, Mr. Levin worked in New York City at Credit Suisse (now part of UBS), where he worked on initial public offerings, follow-on equity offerings, and debt financings for NYSE-listed companies. He previously held corporate finance and controller positions at Broadridge Financial Solutions (NYSE: BR), where his responsibilities included acquisition accounting and post-merger integration, and served as Financial Reporting Manager at Overseas Shipholding Group (now International Seaways, NYSE: INSW). He began his career in the audit practice of PricewaterhouseCoopers (PwC) in its San Jose, California and Tel Aviv offices. Mr. Levin holds a Master of Business Administration (MBA) from the NYU Stern School of Business and a Bachelor of Arts in Economics and Accounting from Ben-Gurion University of the Negev. He is a Certified Public Accountant (CPA) in both the United States and Israel.

“I am thrilled to join Duke Robotics at such an exciting stage in its development,” said Avi Levin, incoming Chief Financial Officer. “Duke has developed innovative, proprietary drone technologies that I believe address clear and urgent operational needs across critical industries. With a strong public company platform on Nasdaq and energized leadership under Yiftach, the Company is positioned to pursue its growth strategy. I look forward to partnering closely with Yiftach, our Board of Directors, and our talented team to strengthen our financial foundation, support our strategic expansion, and drive long-term value for our shareholders.”

About Duke Robotics
Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) develops advanced stabilization and autonomous robotic drone systems for both civilian and defense markets. The Company’s Insulator Cleaning Drone (IC Drone) is a first-of-its-kind, drone-enabled system for cleaning and monitoring high-voltage electric utility insulators. Leveraging Duke’s technologies, the IC Drone provides a safer, more efficient, and cost-effective alternative method. AEROTRACE™ is the Company’s AI-powered aerial monitoring and intelligence platform for infrastructure operators, designed to deliver actionable insights for asset assessment and proactive maintenance. In defense, through a collaboration agreement with Elbit Systems Land Ltd. (“Elbit”), the Bird of Prey weapons drone system is an agile, fully stabilized remote weapon system designed for non-line-of-sight and stand-off engagements, marketed by Elbit under the brand name Bird of Prey (formerly known as TIKAD). For additional Company information, please visit https://dukeroboticsys.com and follow us on Twitter (X) and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Words such as “future” and similar expressions, or future or conditional verbs such as “will,” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs, assumptions, and information currently available to us. For example, we are using forward-looking statements when we discuss the leadership transition and its anticipated benefits, the anticipated timing of Mr. Levin’s commencement of employment, the expected ongoing advisory role of Mr. Zakai, the anticipated benefits of Mr. Levin’s financial leadership and transaction background to the Company’s strategy and capital structure, the Company’s ability to accelerate operational execution and pipeline expansion, and the Company’s opportunities across the defense and energy-infrastructure sectors and beyond. Our actual results may differ materially from those expressed or implied due to known or unknown risks and uncertainties. These include, but are not limited to, risks related to the successful integration of new leadership, the successful market adoption of our technologies, the continued development and refinement of our technology, our ability to effectively collaborate with Elbit Systems, fluctuations in foreign currency exchange rates, operational challenges associated with marketing activities in new markets, economic conditions that may affect defense spending and infrastructure investment, geopolitical factors that could impact business operations, regulatory challenges in various regions, and competition from technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and any subsequent filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Company Contact:
Duke Robotics Corp.
invest@dukeroboticsys.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
duke@arxhq.com

Duke Robotics Corp. is issuing this corrected release primarily to remove an incorrect reference to the annual revenues of RAD Data Communications from the description of Chief Financial Officer Avi Levin’s prior experience and to make certain other immaterial corrections to Mr. Levin’s biographical information.

Strengthens Executive Leadership Team to Accelerate Growth Plans as Company Seeks to Scale Innovative Drone Platforms Across Defense and Civilian Markets

FT. LAUDERDALE, FL, Oct. 02, 2026 (GLOBE NEWSWIRE) — / CORRECTING / Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) (“Duke Robotics” or the “Company”), a leader in advanced robotics and drone-based solutions for civilian and defense markets, today announced the appointment of Avi Levin as Chief Financial Officer, effective October 1, 2026. Mr. Levin succeeds Shlomo Zakai, who is expected to continue providing financial and corporate consulting services to the Company to support a seamless transition of financial operations.

The appointment comes as Duke Robotics enters an accelerated growth phase following its recent Nasdaq uplisting and the arrival of Chief Executive Officer Yiftach Kleinman. As the Company looks to scale commercial adoption of its drone platforms across defense and civilian markets, and expand its offerings, the Company believes Mr. Levin will play a key role in developing Duke’s financial strategy, capital allocation, and corporate initiatives to support its growing operational footprint and strategic expansion plans.

“Since assuming the role of Chief Executive Officer, my focus has been to accelerate our operational tempo and assemble the executive leadership required to execute our growth strategy,” said Yiftach Kleinman, Chief Executive Officer of Duke Robotics. “Duke is at a pivotal inflection point. In the civilian sector, our utility grid solutions are commercially validated and addressing an urgent need for power infrastructure resilience amid rising geopolitical challenges and surging energy demand associated with, among other things, artificial intelligence. In defense, our battle-tested platforms are advancing toward broader commercialization. Bringing on an executive of Avi’s caliber is central to pursuing this market opportunity. He brings a rare combination of deep capital markets experience, proven public company CFO leadership, and strategic transaction expertise that we believe will be instrumental in scaling our business. On behalf of our Board of Directors and the entire Company, I also want to thank Shlomo Zakai for his dedicated financial stewardship through our Nasdaq uplisting, and we look forward to his continued support.”

Mr. Levin is an accomplished financial executive and certified public accountant with more than two decades of corporate finance, capital markets, and institutional leadership experience across the United States and Israel. Throughout his career, he has raised more than $130 million through private placements and public offerings with Nasdaq-listed issuers. He previously served as Chief Financial Officer of Ability Inc. (NASDAQ: ABIL), where he helped lead three Nasdaq offerings, raising an aggregate of $78 million. He also served as Chief Financial Officer of RAD Data Communications, a leading global telecommunications provider, where he managed a 49-person global finance and IT organization across 11 subsidiaries and led the company’s official Nasdaq IPO readiness initiative. Mr. Levin also served as Chief Financial Officer of enterprise AI software provider BlackSwan Technologies where he was part of their institutional financing round. Most recently, he served as a senior financial advisor and executive consultant, advising late-stage technology companies on U.S. capital raising, IPO readiness, and strategic transactions.

Earlier in his career, Mr. Levin worked in New York City at Credit Suisse (now part of UBS), where he worked on initial public offerings, follow-on equity offerings, and debt financings for NYSE-listed companies. He previously held corporate finance and controller positions at Broadridge Financial Solutions (NYSE: BR), where his responsibilities included acquisition accounting and post-merger integration, and served as Financial Reporting Manager at Overseas Shipholding Group (now International Seaways, NYSE: INSW). He began his career in the audit practice of PricewaterhouseCoopers (PwC) in its San Jose, California and Tel Aviv offices. Mr. Levin holds a Master of Business Administration (MBA) from the NYU Stern School of Business and a Bachelor of Arts in Economics and Accounting from Ben-Gurion University of the Negev. He is a Certified Public Accountant (CPA) in both the United States and Israel.

“I am thrilled to join Duke Robotics at such an exciting stage in its development,” said Avi Levin, incoming Chief Financial Officer. “Duke has developed innovative, proprietary drone technologies that I believe address clear and urgent operational needs across critical industries. With a strong public company platform on Nasdaq and energized leadership under Yiftach, the Company is positioned to pursue its growth strategy. I look forward to partnering closely with Yiftach, our Board of Directors, and our talented team to strengthen our financial foundation, support our strategic expansion, and drive long-term value for our shareholders.”

About Duke Robotics
Duke Robotics Corp. (Nasdaq: DUKR; DUKRW) develops advanced stabilization and autonomous robotic drone systems for both civilian and defense markets. The Company’s Insulator Cleaning Drone (IC Drone) is a first-of-its-kind, drone-enabled system for cleaning and monitoring high-voltage electric utility insulators. Leveraging Duke’s technologies, the IC Drone provides a safer, more efficient, and cost-effective alternative method. AEROTRACE™ is the Company’s AI-powered aerial monitoring and intelligence platform for infrastructure operators, designed to deliver actionable insights for asset assessment and proactive maintenance. In defense, through a collaboration agreement with Elbit Systems Land Ltd. (“Elbit”), the Bird of Prey weapons drone system is an agile, fully stabilized remote weapon system designed for non-line-of-sight and stand-off engagements, marketed by Elbit under the brand name Bird of Prey (formerly known as TIKAD). For additional Company information, please visit https://dukeroboticsys.com and follow us on Twitter (X) and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Words such as “future” and similar expressions, or future or conditional verbs such as “will,” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs, assumptions, and information currently available to us. For example, we are using forward-looking statements when we discuss the leadership transition and its anticipated benefits, the anticipated timing of Mr. Levin’s commencement of employment, the expected ongoing advisory role of Mr. Zakai, the anticipated benefits of Mr. Levin’s financial leadership and transaction background to the Company’s strategy and capital structure, the Company’s ability to accelerate operational execution and pipeline expansion, and the Company’s opportunities across the defense and energy-infrastructure sectors and beyond. Our actual results may differ materially from those expressed or implied due to known or unknown risks and uncertainties. These include, but are not limited to, risks related to the successful integration of new leadership, the successful market adoption of our technologies, the continued development and refinement of our technology, our ability to effectively collaborate with Elbit Systems, fluctuations in foreign currency exchange rates, operational challenges associated with marketing activities in new markets, economic conditions that may affect defense spending and infrastructure investment, geopolitical factors that could impact business operations, regulatory challenges in various regions, and competition from technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and any subsequent filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Company Contact:
Duke Robotics Corp.
invest@dukeroboticsys.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
duke@arxhq.com

Duke Robotics Corp. is issuing this corrected release primarily to remove an incorrect reference to the annual revenues of RAD Data Communications from the description of Chief Financial Officer Avi Levin’s prior experience and to make certain other immaterial corrections to Mr. Levin’s biographical information.